---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002631"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:14:59.991941+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eloxx Pharmaceuticals restructures debt; issues stock and warrants for $2M loan assignment

## Summary
- Entered Fifth Amendment to Hercules Loan Agreement; $2M Tranche 1B Advance assigned to SD MF 4 LLC.
- Issued 157,138 shares of common stock, pre-funded warrant for 471,508 shares, and warrant for 150,000 shares to assignee in exchange for debt assumption.
- No cash proceeds from equity issuance; loan financial covenant for minimum cash balance removed for assigned tranche.
- Interest may be paid in-kind on Tranche 1B; principal amortization deferrable at assignee's option.
- Company must file resale registration statement within 15 days; exercise prices: pre-funded $0.001, additional $1.18.

## SEC filing metadata
- accession: 0001104659-24-002631
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465924002631/0001104659-24-002631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465924002631/tm242562d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002631
- JSON: https://secwatch.observer/filing/0001104659-24-002631.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002631.txt

## Key facts
- Material Agreements
  Eloxx Pharmaceuticals, Inc. amended Fifth Amendment to the Loan and Security Agreement with Hercules Capital, Inc., Hercules Capital IV, L.P., Zikani Therapeutics, Inc., Eloxx Pharmaceuticals Ltd. (effective 2024-01-09).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Hercules Capital, Inc., Hercules Capital IV, L.P., Zikani Therapeutics, Inc., Eloxx Pharmaceuticals Ltd.
  - Effective: 2024-01-09
  source text: On January 9, 2024 (the “Closing Date”), Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Fifth Amendment to the Loan and Security Agreement (the “Fifth Amendment”) by and among (i) Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent, and collateral agent, (ii) Hercules Capital IV, L.P., (collectively referred to as the “Lenders”), as a lender, (iii) the Company, as a borrower, (iv) Zikani Therapeutics, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, as a borrower (together with the Company, the “Borrower”), and (v) Eloxx Pharmaceuticals Ltd., an Israeli company and wholly-owned subsidiary of the Company (together with the Lenders and the Borrower, the “Parties”), which amended certain terms of the Loan and Security Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465924002631/0001104659-24-002631-index.htm
- Material Agreements
  Eloxx Pharmaceuticals, Inc. entered into Purchase Agreement with SD MF 4 LLC (effective 2024-01-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: SD MF 4 LLC
  - Effective: 2024-01-09
  source text: On the Closing Date, the Company also entered into a securities purchase agreement (the “Purchase Agreement”) with the Assignee (the “Purchaser”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465924002631/0001104659-24-002631-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.